The Spectrum and Types of Adverse Side Effects to Biological Immune Modulators: A Proposal for New Classification
Marcela Zemková1,2, L. Jebavý3,4, J. Kotlářová1, J. Vlček1, R. H. B. Meyboom2,5
1Department of Social and Clinical Pharmacy, School of Pharmacy Hradec Králové, Charles University in Prague, University Hospital and Medical Faculty Hradec Králové, Hradec Králové, Czech Republic 2Uppsala Monitoring Centre, WHO Collaborating Centre for International Drug Monitoring, Uppsala, Sweden 3Department of Clinical Haematology, 2nd Internal Clinic, Charles University in Prague, University Hospital and Medical Faculty Hradec Králové, Hradec Králové, Czech Republic 4Department of Field Internal Medicine, Faculty of Military Health Sciences, University of Defence Hradec Králové, Hradec Králové, Czech Republic 5Department of Pharmacoepidemiology & Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences, Utrecht, Netherlands
Received February 2007
Accepted April 2007
Crossref Cited-by Linking
Lopes Luciane Cruz, Silveira Miriam Sanches do Nascimento, Camargo Iara Alves de, Barberato-Filho Silvio, Del Fiol Fernando de Sá, Osorio-de-Castro Claudia Garcia Serpa: Biological drugs for the treatment of psoriasis in a public health system. Rev. Saúde Pública2014, 48, 651. <https://doi.org/10.1590/S0034-8910.2014048005109>
